ClinicaliQ Trial Snapshot
- A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder — Recruiting • Phase II • Oncology • NCT07475806.
- What is being tested: The combination of enfortumab vedotin (an antibody-drug conjugate targeting Nectin-4) with pembrolizumab (a PD-1 checkpoint inhibitor) as a bladder-preserving alternative to radical cystectomy in muscle-invasive bladder cancer patients.
- Patient eligibility overview: Adults with newly diagnosed muscle-invasive bladder cancer who are candidates for radical cystectomy; typically includes patients with adequate organ function and performance status, excluding those with prior systemic chemotherapy or certain contraindications to immunotherapy.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
People with a type of bladder cancer called muscle-invasive bladder cancer have cancer that has spread into the muscle wall of the bladder. The standard treatment is to have chemotherapy, followed by surgery to completely remove the bladder. This has a significant impact on people with long-term life-altering changes. There are also limited options for people who cannot have chemotherapy or who do not want their bladder removed. Studies show that enfortumab vedotin, when given with pembrolizumab, can help people with advanced bladder cancer. This treatment has also worked well…
Eligibility Snapshot
- : * Participant has histologically-confirmed MIBC, stage cT2-T4aN0M0 or T1-T4aN1M0. NOTE: urothelial carcinomas (UCs) not originating from the bladder (e.g., upper tract [ureters, renal pelvis], urethra) are not eligible. UCs invading into the prostatic stroma with no histologic muscle invasion is allowed, provided that the extent of disease is confirmed via imaging. * Participant has predominant UC histology (≥ 50%). NOTE: Participants with mixed histology are eligible provided the urothelial component is ≥ 50% (participants whose tumors contain predominant [≥ 50%] plasmacytoid variant are not eligible). Participants whose tumors contain any neuroendocrine histology are not eligible. * Participant is deemed eligible for radical cystectomy and pelvic lymph node dissection. * Participant has accessible archival tumor tissue from the primary tumor, for which source and availability have been confirmed prior to study intervention. If no archival tumor tissue is available, the participant will have a biopsy to obtain tumor tissue prior to study intervention. * Participant has Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2. * Have a transurethral resection of a bladder tumor within 60 days (+14 days) prior to, or during screening (from the date of informed consent form signature).
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.